Clinical Trial Update: L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating L-NMMA effects on GLP-2–mediated intestinal lipoprotein release in hyperlipidemia; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemias

Drugs mentioned

• L-NMMA (NG-monomethyl-L-arginine)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hyperlipidemias | Phase 2, Phase 3 | Status: COMPLETED